1. All Products
  2. E - Medical equipment
  3. DANTROLENE sodium, 20mg, powder, vial
Public Pricelist

DANTROLENE sodium, 20mg, powder, vial

https://unicat.msf.org/cat/product/94011
STD DINJDANT2V-

Valid Article

The product is supplied (and stored) sterile, it must remain sterile until its use. Sterile = state of being free from all living microorganisms.
20 - Muscle relaxants (peripherally-acting) and cholinesterase inhibitors
Classification of the medicines in groups and subgroups according to their therapeutic use. The classification used by MSF is based on the WHO Model List of Essential Medicines.
M03CA01
Anatomical Therapeutic Chemical Classification according to WHOCC
PME
The order of this product needs to be justified and is only acceptable under certain conditions.
1525
Thermosensitive codes are defined for storage and transportation temperature requirements of the products.
OC subscriptions: included in supply or field order tools (e.g. UniField)
SC subscriptions: included in supply or field tools
OC validations: approved for procurement and use by an OC for international or local orders specifying context and activity in Medical Standard Lists (MSL)
https://www.unicat.msf.org/web/image/product.template/582324/image_1920?unique=ecb2ae4

This combination does not exist.

Add article to list

   
Create Cancel

Add Kit To Wishlist

   
Create Cancel

DANTROLENE

Therapeutic Action

Muscle relaxant, directly acting agent

Indications

Malignant Hyperthermia (MH) induced by inhaled anaesthetic agents (e.g.isoflurane, sevoflurane, halothane) or by succinylcholine, in combination with appropriate supportive measures.

Some restricted information has been hidden. Sign in to see this information

Instructions for use

  • Reconstitute the powder vial with 60 ml of water for injection. Shake the vial until complete dissolution of the powder.
  • When drawing up the reconstituted solution into the syringe, use the single-use filtration device provided.
  • Remove the filtration device from the syringe before connecting it to an IV catheter or IV infusion line.

Use in Malignant Hyperthermia:

  • Posology: 2.5mg/kg (8-10 vials in adults). In most cases, a total dose of up to 10mg/kg over 24 hours is sufficient.
  • Must be given as immediate IV bolus at the first signs of malignant hyperthermia (e.g., tachycardia, tachypnoea, central venous desaturation, hypercarbia, metabolic acidosis, skeletal muscle rigidity, increased utilisation of the anaesthesia circuit carbon dioxide absorber, cyanosis, mottling of the skin, and, frequently fever).
  • Dantrolene should only be administered by anaesthesia or intensive care specialists in hospital settings equipped with ventilation support and resuscitation equipment.
  • Dantrolene must be readily available in operating suites and ready to be administered within 10 minutes of recognising a malignant hyperthermia crisis.
  • For further details on posology and management, contact your anaesthesia advisor.

Precautions for Use

Due to the potential presence of undissolved crystals or particles in the reconstituted solution (which may increase the risk of injection site reactions or tissue necrosis), the use of a filtration device is required at all times when drawing up the solution.

Do not mix dantrolene with other IV medicines.

Storage

  • Below 25ºC - Protect from sunlight
  • After reconstitution, use the product immediately.
  • Discard any unused solution.